Alefacept. Amevive, BG 9273, human LFA-3/Igg fusion protein, LFA 3, LFA 3 TIP LFA 3/CD2, LFA-3/Igg fusion protein, LFA3TIP, recombinant LFA-3/Igg1 human fusion protein, recombinantly engineered LFA-1/Igg1 human fusion protein.
D000077944:Alefacept; D000818:Animals; D002986:Clinical Trials as Topic; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy*
D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077944:Alefacept